| 26082-78-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• CAS: 26082-78-0
• 化学式: C14H24N2NaO10
• 分子量: 403.34
• InChiKey: AUZIBXIUQNRQGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.42
• 重原子数：
  27
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  174
• 氢给体数：
  4
• 氢受体数：
  12

文献信息

• Dimeric small molecule potentiators of apoptosis
  申请人：Harran G. Patrick

  公开号：US20050197403A1

  公开（公告）日：2005-09-08

  Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.

  Caspase活性和细胞凋亡会通过通用公式M1-M2的活性二聚Smac肽模拟物来促进，其中M1和M2是单体Smac模拟物，L是共价连接剂。将靶癌细胞或炎症细胞与有效量的活性二聚Smac模拟物接触，并检测靶细胞凋亡的增加。接触步骤可以通过给予含有治疗有效量的二聚模拟物的药物组合物来实现，个体可能同时或先前接受放射治疗或化疗以治疗肿瘤增生病理。
• [EN] APOPTOSIS-INDUCING COMPOUNDS<br/>[FR] COMPOSES INDUISANT L'APOPTOSE
  申请人：TRINITY COLLEGE DUBLIN

  公开号：WO2001058904A1

  公开（公告）日：2001-08-16

  The invention relates to a pharmaceutical composition comprising an apoptosis-inducing amount of a compound having general formula (I), wherein: (i) R1 represents an unsubstituted C6 or C10 aryl group; or a C6 aryl group substituted with Me or OMe; (ii) A represents O, S or S partially oxidized to sulfoxide; (iii) the cyclic group labelled F represents an unsubstituted C6 or C10 aryl-fused group or a C5 heteroaryl-fused group (nitrogen as heteroatom) or a benzo-fused system substituted with ethoxycarbonyl function; (iv) and Y represents the group (A) wherein R2 and R3 are independently hydrogen; or methyl; or Y represents the group CH3 or a (CH2)2CH3 group; or an unsubstituted C5 heteroaryl group (nitrogen as heteroatom). The compositions may be used for the treatment of tumours or other cancerous conditions, such as CML (chronic myeloid leukaemia), AML, in AIDS-related lymphomas (such as Karpowski's sarcoma, a sub-cutaneous lymphoma) and used as apoptotic agents in the treatment of cancers generally.

  本发明涉及一种药物组合物，包含一定量的通式（I）化合物，其诱导细胞凋亡的作用，其中：（i）R1代表未取代的C6或C10芳基；或取代有Me或OMe的C6芳基；（ii）A代表O，S或部分氧化为亚砜的S；（iii）标记为F的环状基团代表未取代的C6或C10芳基融合基团或取代有乙氧羰基的苯融合系统或C5杂环芳基融合基团（杂原子为氮）；（iv）Y代表基团（A），其中R2和R3独立地代表氢；或甲基；或Y代表基团CH3或（CH2）2CH3基团；或未取代的C5杂环芳基（杂原子为氮）。该组合物可用于治疗肿瘤或其他癌症疾病，如慢性髓性白血病（CML）、急性髓性白血病（AML）、艾滋病相关淋巴瘤（如卡波夫斯基肉瘤，一种皮下淋巴瘤）并可作为凋亡剂用于治疗各种癌症。
• Apoptotic compounds
  申请人：Board of Regents, The university of Texas System

  公开号：US20040077542A1

  公开（公告）日：2004-04-22

  The invention provides methods and compositions for enhancing apoptosis of pathogenic cells. The general method comprises the of contacting the cells with an effective amount of an AV peptoid, wherein the AV peptoid is a peptide comprising AX 1 , wherein X 1 is V, I or L, or a peptide mimetic thereof, which interacts with an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis, wherein apoptosis of the pathogenic cells is enhanced. The subject compositions encompass pharmaceutical compositions comprising a therapeutically effective amount of a subject AV peptoid in dosage form and a pharmaceutically acceptable carrier, wherein the AV peptoid is a peptide comprising AX 1 , wherein X 1 is V, I or L, or a peptide mimetic thereof, which inhibits the activity of an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis. The invention also provides assays for identifying agents which modulates the interaction of an AV peptoid with an IAP, active compounds identified in such screens and their use in the foregoing compositions and therapeutic methods.

  本发明提供了增强致病细胞凋亡的方法和组合物。一般方法包括将细胞与有效量的AV肽类接触，其中AV肽类是包含AX1的肽类，其中X1为V、I或L，或其肽类类似物，通过IAP结合、procaspase-3激活或促进凋亡等测量方式与凋亡抑制蛋白（IAP）相互作用，从而增强致病细胞的凋亡。所述组合物包括在制剂中含有治疗有效量的AV肽类和药学可接受的载体的制药组合物，其中AV肽类是包含AX1的肽类，其中X1为V、I或L，或其肽类类似物，通过IAP结合、procaspase-3激活或促进凋亡等测量方式抑制凋亡抑制蛋白（IAP）的活性。本发明还提供了用于识别调节AV肽类与IAP相互作用的试剂的测定方法，以及在此类筛选中鉴定出的活性化合物及其在上述组合物和治疗方法中的应用。
• Dimeric Small Molecule Potentiators of Apoptosis
  申请人：Harran Patrick G.

  公开号：US20080119532A1

  公开（公告）日：2008-05-22

  Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.

  Caspase活性和细胞凋亡可以通过使用通式为M1-L-M2的活性二聚体Smac肽类似物来促进，其中M1和M2部分是单体Smac类似物，L是共价连接剂。靶向癌细胞或炎症细胞与有效量的活性二聚体Smac类似物接触，检测到靶细胞凋亡的增加。接触步骤可以通过给予含有治疗有效量的二聚体类似物的制剂来实现，其中个体可能同时或先前接受放射治疗或化疗以治疗肿瘤增生病理。
• Method for the identification of compounds susceptible to inhibit inflammation
  申请人：Apoxis SA

  公开号：EP1746167A1

  公开（公告）日：2007-01-24

  The present invention concerns a method for the identification of compounds susceptible to inhibit the activity of the inflammasome comprising contacting at least one compound to be screened with an assay appropriate to selectively detect and quantify the inflammasome formation in vitro. The invention also concerns the use of the compound or group of compounds being selected by the method according to the invention in the development of drugs to be used in the treatment of conditions where control of inflammation is needed.

  本发明涉及一种鉴定易抑制炎症小体活性的化合物的方法，该方法包括将至少一种待筛选的化合物与适合于选择性检测和量化体外炎症小体形成的检测方法接触。本发明还涉及根据本发明的方法筛选出的化合物或化合物组在药物开发中的用途，这些药物将用于治疗需要控制炎症的病症。